Product category:
Contract research
News Release from: Lipomics Technologies
Edited by the Laboratorytalk Editorial
Team on 16 February 2007
Diagnostic panels to be based on
clinical trials
Lipomics Technologies enters agreement with Isis Pharmaceuticals to provide lipid-focused support of preclinical and clinical trial testing for various compounds to treat metabolic disease
Lipomics will retain exclusive rights to develop diagnostic applications based on the data from the studies, while Isis will retain all therapeutic rights Lipomics seeks to partner with drug companies that see the value in developing companion diagnostic tests that increase the efficacy, safety and cost-effectiveness of a therapeutic
Sanjay Bhanot, vice president, metabolic diseases R+D at Isis, commented: "We are impressed with Lipomics's capabilities and look forward to working with it as we assess the lipid profiles of compounds we have in our metabolic disease development pipeline".
"We look forward to working with Isis.
"We believe our approach, which focuses on providing plasma-based mechanistic markers of lipid metabolism, will help to advance their compounds through the clinic," said Steve Watkins, president and chief scientific officer at Lipomics.
• Lipomics Technologies: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
